Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05683964 · ClinicalTrials.gov registry record · Early Phase 1

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

A Early Phase 1 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Beth Israel Deaconess Medical Center.

Active
Registry status
Early Phase 1
Development phase
9
Enrollment target
1
Study location

NCT05683964 is a Early Phase 1 study of Prostate Cancer and Prostate Adenocarcinoma that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 9 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05683964, a Early Phase 1 study of Prostate Cancer and Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy. The names of the treatment interventions involved in this study are: * Androgen receptor antagonist monotherapy. * PSMA PET/CT scan It is expected that about 15 people will take part in this research study. Participation in this research study is expected to last about 4 weeks.

Conditions Studied

Prostate Cancer Prostate Adenocarcinoma Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

  • DRUG Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
  • DIAGNOSTIC_TEST Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2023-01-19
Est. Completion 2026-09-01
Phase Early Phase 1

Sponsor

Beth Israel Deaconess Medical Center

488 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05683964

The ClinicalTrials.gov registry entry for NCT05683964 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi] is the first listed.

NCT05683964 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05683964 about?

NCT05683964 is a clinical study titled "Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression". The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA leve...

What is the current status of trial NCT05683964?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2023-01-19. Estimated completion is 2026-09-01.

What conditions does trial NCT05683964 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

What interventions are being tested in trial NCT05683964?

The interventions under investigation include: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi] (DRUG), Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05683964?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05683964 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Prostate Adenocarcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.